This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 75 clinical trial centers. The study will continue until 2 years after the last subject is enrolled at any study site or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).
Drug: Inhaled Treprostinil
Primary Investigator: Engel